U.S., EUROPE, AND ASIA PACIFIC MOLECULAR DIAGNOSTICS MARKET ANALYSIS

U.S., Europe, and Asia Pacific Molecular Diagnostics Market, by Product Type (Reagents and Kits & Instruments), by Technology (PCR-based (Liquid Biopsy Testing, Tissue Testing) and NGS-based (Liquid Biopsy Testing, Tissue Testing)), by Application, (Genetic Testing, Oncology, Microbiology, STDs, Blood Screening, Virology, Tissue Typing, Prenatal Diagnosis, Others), by End Users, (Hospitals, Clinics, and Ambulatory Surgery Centers), and by Region (U.S., Europe, and Asia Pacific) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022
Code : CMI4919
Pages :90
Formats :
Excel and PDF
Industry : Medical Devices

U.S., Europe, and Asia Pacific Molecular Diagnostics MarketSize and Trends

Figure 1. U.S., Europe, and Asia Pacific Molecular Diagnostics Market (US$ Mn), By Product Type, 2021

Figure 1.1. U.S., Europe, and Asia Pacific Molecular Diagnostics Market (US$ Mn), By Product Type, 2028

U.S., Europe, and Asia Pacific Molecular Diagnostics Market – Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China.

The COVID-19 has impacted molecular diagnostics testing and research for non-COVID applications. The deployment of COVID-19 molecular diagnostics slowed down due to lack of equipment, insufficient lab environmental protection, and reagent capacity. Even the laboratory professionals faced immediate urgent testing demands. On non-COVID biologic research, a less adverse consequence has been noticed which also includes molecular diagnostics. By reallocation and equipment, the non-COVID research has been hampered a lot since past year.

Furthermore, among the sectors, hospital based clinical research were most severely affected.

Figure 2. U.S., Europe, and Asia Pacific Molecular Diagnostics Market (US$ Mn), By Technology, 2021